# Coding Pitfalls Case Scenarios

## Breast Case Scenario

The summary below is an aide meant to help follow along with the presentation. Participants do **not** need to complete the scenario prior to the session.

History:

A 42 year old female presents with a palpable left breast mass. The axilla area was negative for enlarged lymph nodes.

Imaging:

* Mammogram showed a left breast mass at 10 o’clock measuring 3cm.
* Ultrasound of the left breast: 2 cm mass @10:00 and a left axillary lymph node measuring 1.1 cm

Pathology:

* Biopsy of the breast @10:00: positive for carcinoma NST with tubular carcinoma, NG grade 2, areas of high grade DCIS
	+ ER 95% (positive)
	+ PR 81-90% (positive)
	+ Ki-67 44% (H)
	+ HER2 by Immunohistochemistry 2+
	+ HER2 by in situ hybridization Positive (amplified)
	+ HER2: CEP17 ratio 1.34
	+ Average HER2 signals/nucleus 4.75
	+ Average CEP17 signals/nucleus 3.55
* Biopsy of left axillary lymph node: Negative for malignancy
* Mastectomy:
	+ No residual carcinoma (complete PR)
	+ 0/4 SLN, IHC negative

Treatment:

* Neoadjuvant chemotherapy: 6 cycles of TCHP
* Surgery: Bilateral nipple sparing mastectomy, sentinel lymph node biopsy, tissue expander reconstruction.

Discharge Summary:

* Patient had a complete pathologic response to neoadjuvant treatment.

|  |
| --- |
| Scenario 1-Breast |
| Primary Site |  | Clinical Grade |  | Tumor Size Clinical |  |
| Histology |  | Pathological Grade |  | Tumor Size Pathological |  |
| Behavior |  | Post Therapy Grade |  | Tumor Size Summary |  |
| MP Rule |  |  |
| H Rule |  |
|  |
| Stage Data items |
| Clinical T |  | Pathological T |  | Post-therapy T |  |
| cT Suffix |  | pT Suffix |  | pT Suffix |  |
| Clinical N |  | Pathological N |  | Post-therapy N |  |
| cN Suffix |  | pN Suffix |  | pN Suffix |  |
| Clinical M |  | Pathological M |  | Post-therapy M |  |
| Clinical Stage  |  | Pathological Stage |  | Post-therapy Stage |  |
|  |
| Summary Stage 2018  |  |
| EOD Primary Tumor |  |
| EOD Regional Nodes |  |
| EOD Mets  |  |
| Regional Nodes Positive |  |
| Regional Nodes Examined |  |
| Sentinel Nodes Positive |  |
| Sentinel Nodes Examined |  |
|  |
| SSDI’s |
| *Positive AxLN Level I-II* |  |
| ER Summary  |  |
| ER Percent Positive |  |
| ER Allred Score |  |
| PR Summary |  |
| PR Percent Positive |  |
| PR Allred Score |  |
| HER2 IHC Summary |  |
| HER2 ISH Summary |  |
| HER2 Overall Summary |  |
| HER2 ISH DP Ratio |  |
| HER2 ISH DP Copy No |  |
| HER2 ISH SP Copy No |  |
| Ki-67 (MIB-1) |  |
| Oncotype DX Recur Score |  |
| Oncotype Dx Risk Level Invasive |  |
| Oncotype DX Recur Score - DCIS |  |
| Oncotype Dx Risk Level – DCIS |  |
| Multigene Signature Method |  |
| Multigene Signature Result |  |
| Response Neoadjuvant Therapy  |  |
|  |
| Diagnostic Staging Procedure |  |
|  |
| Surgery |
| Surgical Procedure of Primary Site |  |
| Scope of Regional Lymph Node Surgery |  |
| Surgical Procedure/ Other Site |  |
| Systemic Therapy |
| Chemotherapy |  |
| Hormone Therapy |  |
| Immunotherapy |  |
| Hematologic Transplant |  |
| Systemic/ Surgery Sequence |  |
|  |  |
| Radiation |
|  | Phase 1 | Phase 2 | Phase 3 |
| Rad Primary Treatment Volume |  |  |  |
| Rad Treatment Modality |  |  |  |
| Radiation to Draining Lymph Nodes |  |  |  |
| Ext Beam Rad Planning Technique |  |  |  |
| Dose per Fraction |  |  |  |
| Number of Fractions |  |  |  |
| Total Dose |  |  |  |
| # of Phases of Rad Tx to this Volume |  |
| Rad Treatment Discontinued Early |  |
| Total Dose |  |
| Reason no Radiation  |  |

## Colon Case Scenario

**History**

Patient had a transverse colectomy for adenocarcinoma of the transverse colon on 4/25/16. The patient presents today for a follow-up barium enema and colonoscopy.

* Labs: 7/25/18 CEA 17 ng/ml (normal < 3 ng/ml)
* Imaging: 7/25/18
	+ BE: 2.5 cm polypoid lesion at the anastomotic site shows the typical features of colonic CA
	+ CT chest/abd/pel: no evidence of metastasis
* Scopes 7/25/18 Colonoscopy: submucosal tumor located at suture line; biopsies taken
* Treatment 8/24/18 Right hemicolectomy

**Pathology**

7/25/18 Biopsy at anastomosis: Moderately differentiated adenocarcinoma.

8/24/18 Right colon with anastomosis:

* 2.9 cm well differentiated adenocarcinoma with mucinous differentiation at anastomotic site
* Tumor invades muscularis propria;
* LVI: None
* PNI: None
* Proximal, distal, and radial margins free
* 16 lymph nodes negative for metastasis
* A single peritumoral deposit
* MSI low
* KRAS mutated

**Discharge summary**:

Clinicopathological examination showed the lesion was a recurrence of the previous trans-colon cancer, because it was located exactly on the anastomosis and it first showed a feature of submucosal tumor. Plan: FOLFOX

|  |
| --- |
| Scenario 2-Colon |
| Primary Site |  | Clinical Grade |  | Tumor Size Clinical |  |
| Histology |  | Pathological Grade |  | Tumor Size Pathological |  |
| Behavior |  | Post Therapy Grade |  | Tumor Size Summary |  |
| MP Rule |  |  |
| H Rule |  |
|  |
| Stage Data items |
| Clinical T |  | Pathological T |  | Post-therapy T |  |
| cT Suffix |  | pT Suffix |  | pT Suffix |  |
| Clinical N |  | Pathological N |  | Post-therapy N |  |
| cN Suffix |  | pN Suffix |  | pN Suffix |  |
| Clinical M |  | Pathological M |  | Post-therapy M |  |
| Clinical Stage  |  | Pathological Stage |  | Post-therapy Stage |  |
|  |
| Summary Stage 2018  |  |
| EOD Primary Tumor |  |
| EOD Regional Nodes |  |
| EOD Mets  |  |
| Regional Nodes Positive |  |
| Regional Nodes Examined |  |
| Sentinel Nodes Positive |  |
| Sentinel Nodes Examined |  |
|  |
| SSDI’s |
| CEA PreTX Lab Value |  |
| CEA PreTX Interpretation |  |
| Tumor Deposits |  |
| Circumferential Resection Margin |  |
| KRAS |  |
| Microsatellite Instability (MSI) |  |
|  |
| Diagnostic Staging Procedure |  |
|  |
| Surgery |
| Surgical Procedure of Primary Site |  |
| Scope of Regional Lymph Node Surgery |  |
| Surgical Procedure/ Other Site |  |
| Systemic Therapy |
| Chemotherapy |  |
| Hormone Therapy |  |
| Immunotherapy |  |
| Hematologic Transplant |  |
| Systemic/ Surgery Sequence |  |
|  |  |
| Radiation |
|  | Phase 1 | Phase 2 | Phase 3 |
| Rad Primary Treatment Volume |  |  |  |
| Rad Treatment Modality |  |  |  |
| Radiation to Draining Lymph Nodes |  |  |  |
| Ext Beam Rad Planning Technique |  |  |  |
| Dose per Fraction |  |  |  |
| Number of Fractions |  |  |  |
| Total Dose |  |  |  |
| # of Phases of Rad Tx to this Volume |  |
| Rad Treatment Discontinued Early |  |
| Total Dose |  |
| Reason no Radiation  |  |